Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

RECRUITING

Identifier: CI-TRIAL-00119753
Entity page: /trial/NCT04840602 ↗
Edges: 6

Neighbours: 2 cancers4 drugs
Drawn: 6 of 6 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma condition of …CONDITION_OFderived2 of 2
← condition of	Lymphoplasmacytic Lymphoma registry condition “Lymphoplasmacytic Lymphoma” mapped ONTOLOGY_EXACT	—	—	Lymphoplasmacytic Lymphoma	1	Observed	clinicaltrials	graph →
← condition of	Waldenstrom Macroglobulinemia registry condition “Waldenstrom Macroglobulinemia” mapped ONTOLOGY_EXACT

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma intervention of …INTERVENTION_OFderived4 of 4
← intervention of	Ibrutinibsmall molecule registry intervention “Ibrutinib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Rituximabmonoclonal antibody registry intervention “Rituximab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Venetoclaxsmall molecule registry intervention “Venetoclax” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Zanubrutinibsmall molecule registry intervention “Zanubrutinib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma intervention of …INTERVENTION_OFderived4 of 4

← intervention of

Ibrutinibsmall molecule

registry intervention “Ibrutinib” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Rituximabmonoclonal antibody

registry intervention “Rituximab” (BIOLOGICAL) mapped ALIAS

—